A phase I clinical study to assess safety and immunogenicity of yellow fever vaccine.
Journal
NPJ vaccines
ISSN: 2059-0105
Titre abrégé: NPJ Vaccines
Pays: England
ID NLM: 101699863
Informations de publication
Date de publication:
19 Dec 2022
19 Dec 2022
Historique:
received:
25
08
2022
accepted:
06
12
2022
entrez:
19
12
2022
pubmed:
20
12
2022
medline:
20
12
2022
Statut:
epublish
Résumé
Yellow fever, a mosquito-borne flavivirus infection, is an important public health problem in Africa and Latin America. A Yellow Fever vaccine (YFV) was developed and tested in a study in India. This was a Phase I, open-label, randomized, controlled study where healthy adults received SII YFV intramuscularly (SII YFV IM), SII YFV subcutaneously (SII YFV SC) or STAMARIL
Identifiants
pubmed: 36535976
doi: 10.1038/s41541-022-00595-6
pii: 10.1038/s41541-022-00595-6
pmc: PMC9763341
doi:
Types de publication
Journal Article
Langues
eng
Pagination
170Informations de copyright
© 2022. The Author(s).
Références
Lancet. 2021 Jan 9;397(10269):119-127
pubmed: 33422245
Hum Vaccin Immunother. 2022 Dec 31;18(1):1895644
pubmed: 33974507
Wkly Epidemiol Rec. ;92(25):345-50
pubmed: 28643507
J Clin Virol. 2015 Mar;64:160-73
pubmed: 25453327
N Engl J Med. 2019 Aug 1;381(5):444-454
pubmed: 29443626
Am J Trop Med Hyg. 2005 Mar;72(3):339-46
pubmed: 15772332